AnGes deal with Mitsubishi Tanabe Pharma for Collategene in USA

4 July 2012

AnGes MG (TYO: 4563) has concluded a basic agreement with fellow Japanese drugmaker Mitsubishi Tanabe Pharma (TYO: 4508) for the exclusive marketing rights of Collategene (DNA plasmid with HGF gene) as a treatment for peripheral arterial disease (PAD) in the USA.

AnGes has been seeking for a partner to pursue the global Phase III study regarding Collategene as a treatment for critical limb ischemia (CLI), the severe stage of arteriosclerosis obliterans and Buerger's disease

Once the contract regarding the exclusive marketing rights is concluded, AnGes will receive undisclosed upfront payments and milestone payments. AnGes believes that it can maximize the asset value of Collategene by conducting a prompt global Phase III study centered in the USA which has the biggest market in the world.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK